<DOC>
	<DOCNO>NCT00119613</DOCNO>
	<brief_summary>The purpose study evaluate whether increase maintain hemoglobin concentration darbepoetin alfa , administer platinum-containing chemotherapy subject previously untreated extensive-stage small cell lung cancer ( SCLC ) , increase survival .</brief_summary>
	<brief_title>A Study Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer ( SCLC ) Treated With Platinum Plus Etoposide Chemotherapy With Without Darbepoetin Alfa</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Pathologically proven SCLC , extensivestage Planned receive chemotherapy carboplatin cisplatin plus etoposide every 3 week 6 cycle Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy great equal 3 month Hemoglobin concentration great equal 9.0 g/dL less equal 13g/dL Adequate renal , liver hematopoietic function Subjects must sign date write Institutional Review Board /Independent Ethics Committeeapproved Informed Consent Form Known primary hematologic disorder could cause anemia Brain metastasis either symptomatic treated medication Unstable uncontrolled disease/condition , related affect cardiac function Other know primary malignancy within past 5 year exception curatively treat basal cell carcinoma , squamous cell carcinoma situ cervical carcinoma surgically cured malignancy Iron deficiency Known positive test human immunodeficiency virus infection Received great 2 unit pack red blood cell within 4 week randomization RBC transfusion within 2 week randomization Received rHuEPO darbepoetin alfa therapy within 4 week randomization Previous chemotherapy SCLC Previous radiotherapy except symptom palliation bone brain lesion least 24 hour since prior radiotherapy symptom palliation provide extent radiotherapy make mark bone marrow suppression unlikely Less 30 day since receipt drug device approve indication Pregnant breastfeeding Not use adequate contraceptive precaution Previously randomize study Known hypersensitivity recombinant mammalianderived product ingredient contain study drug Any medical , mental , condition make subject unsuitable participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Hemoglobin</keyword>
	<keyword>Darbepoetin alfa</keyword>
	<keyword>Survival</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Extensive Stage Small Cell Lung Cancer</keyword>
</DOC>